Study of FK778 in Renal Transplant Recipients With Untreated BK Nephropathy

Phase 2 Terminated 45 enrolled Astellas Pharma Inc Astellas Pharma US, Inc. · collab

RandomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this study is to assess the safety and effectiveness of a new oral immunosuppressant agent compared to standard care in renal transplant patients diagnosed with BK nephropathy.

Timeline

Start: 2005-01
Primary completion: —
Completion: 2006-08

Publications

Wajih Z, Karpe KM, Walters GD. Interventions for BK virus infection in kidney transplant recipients. Cochrane Database Syst Rev. 2024 Oct 9;10(10):CD013344. doi: 10.1002/14651858.CD013344.pub2.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	MANITIMUS	Small molecule	—	Oral

Study of FK778 in Renal Transplant Recipients With Untreated BK Nephropathy

Summary

Timeline

Publications

Drugs

Indications